---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-23-008963"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2023-12-05T23:59:59+00:00"
generated_at: "2026-06-07T18:30:32.910272+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# VolitionRx secures ~$5.5M financing from Belgian regional government WE

## Summary
- Total financing €5.0M (~$5.5M) from Wallonie Entreprendre; €2.5M unsecured loan at 8% interest, maturity Dec 2028.
- €2.5M equity component: WE purchases 3,205,431 restricted shares at $0.8337 per share.
- Proceeds for Nu.Q product development, including Nu.Q NETs sepsis diagnostic clinical program.
- Loan drawable in three tranches: €1.5M immediate, €0.5M from June 2024, €0.5M from March 2025.

## SEC filing metadata
- accession: 0001477932-23-008963
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2023-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793223008963/0001477932-23-008963-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793223008963/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-23-008963
- JSON: https://secwatch.observer/filing/0001477932-23-008963.json
- Plain text: https://secwatch.observer/filing/0001477932-23-008963.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.